5-(p-tolyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one | 713517-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5-(p-tolyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
• 英文别名: 5-(4-Methylphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 713517-74-9
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: XZZWWPIWLHRBLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(p-tolyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

  摘要：

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

  DOI：

  10.1021/jm031115r
• 作为产物：
  描述：

  2-氨基-4‘-甲基苯甲酮 在 氨 、 水 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 5-(p-tolyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
  参考文献：
  名称：

  Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

  摘要：

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

  DOI：

  10.1021/jm031115r

文献信息

• New Insight into the Central Benzodiazepine Receptor–Ligand Interactions: Design, Synthesis, Biological Evaluation, and Molecular Modeling of 3-Substituted 6-Phenyl-4<i>H</i>-imidazo[1,5-<i>a</i>][1,4]benzodiazepines and Related Compounds
  作者：Maurizio Anzini、Salvatore Valenti、Carlo Braile、Andrea Cappelli、Salvatore Vomero、Stefano Alcaro、Francesco Ortuso、Luciana Marinelli、Vittorio Limongelli、Ettore Novellino、Laura Betti、Gino Giannaccini、Antonio Lucacchini、Simona Daniele、Claudia Martini、Carla Ghelardini、Lorenzo Di Cesare Mannelli、Gianluca Giorgi、Maria Paola Mascia、Giovanni Biggio

  DOI：10.1021/jm2001597

  日期：2011.8.25

  3-Substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds were synthesized as central benzodiazepine receptor (CBR) ligands. Most of the compounds showed high affinity for bovine and human CBR, their Ki values spanning from the low nanomolar to the submicromolar range. In particular, imidazoester 5f was able to promote a massive flow of 36Cl– in rat cerebrocortical synaptoneurosomes

  合成了3-取代的6-苯基-4 H-咪唑并[1,5- a ] [1,4]苯并二氮杂and和相关化合物作为中心苯并二氮杂receptor受体（CBR）配体。大多数化合物显示出对牛和人CBR的高亲和力，它们的K i值范围从低纳摩尔到亚微摩尔范围。特别是，imidazoester 5F是能够促进了大规模的流动36氯-在大鼠大脑皮层synaptoneurosomes与典型的完全激动剂的重叠其功效特征。化合物5f然后在小鼠中检查其药理作用，证明其是安全的抗焦虑药，没有经典的1,4-苯并二氮杂卓类药物的令人不悦的肌松和健忘作用。此外，一些选择的化合物的选择性已经评估了重组α 1 β 2 γ 2 L，α 2 β 1 γ 2 L，和α 5 β 2 γ 2大号人GABA甲受体。最后，将某些化合物连同Cromer GABA A同源性模型中的分子动力学模拟一起进行了分子对接计算。
• Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists
  作者：Martin H. Bolli、Judith Marfurt、Corinna Grisostomi、Christoph Boss、Christoph Binkert、Patrick Hess、Alexander Treiber、Eric Thorin、Keith Morrison、Stephan Buchmann、Daniel Bur、Henri Ramuz、Martine Clozel、Walter Fischli、Thomas Weller

  DOI：10.1021/jm031115r

  日期：2004.5.1

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.
• Structure–Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin
  作者：Hajer Abdelkafi、Aurélien Michau、Valérie Pons、Flora Ngadjeua、Alexandra Clerget、Lilia Ait Ouarab、David-Alexandre Buisson、David Montoir、Lucie Caramelle、Daniel Gillet、Julien Barbier、Jean-Christophe Cintrat

  DOI：10.1021/acs.jmedchem.0c00298

  日期：2020.8.13

  High-throughput screening has shown that Retro-1 inhibits ricin and Shiga toxins by diminishing their intracellular trafficking via the retrograde route, from early endosomes to the Golgi apparatus. To improve the activity of Retro-1, a structure-activity relationship (SAR) study was undertaken and yielded an analogue with a roughly 70-fold better half-maximal effective concentration (EC50) against Shiga toxin cytotoxicity measured in a cell protein synthesis assay.